LON:AREC Arecor Therapeutics Interim Earnings Report GBX 69.40 +3.40 (+5.15%) As of 12:08 PM Eastern ProfileEarnings History Arecor Therapeutics EPS ResultsActual EPS-GBX 7Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AArecor Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArecor Therapeutics Announcement DetailsQuarterInterimDate9/25/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Arecor Therapeutics Earnings HeadlinesArecor Therapeutics (LON:AREC) Trading 3.3% Higher - Time to Buy?May 28, 2026 | americanbankingnews.comArecor Therapeutics CEO on advancing ultra-rapid insulin trial and oral GLP-1 - ICYMIApril 17, 2026 | proactiveinvestors.com.au$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…June 5 at 1:00 AM | Paradigm Press (Ad)Arecor targets broader AT278 partnership as phase II trial nearsApril 13, 2026 | uk.finance.yahoo.comArecor targets phase II trial for AT278 in 2026 - ICYMIFebruary 14, 2026 | uk.finance.yahoo.comArecor targets phase II insuling trial for 2026 after successful 2025February 11, 2026 | finance.yahoo.comSee More Arecor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arecor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arecor Therapeutics and other key companies, straight to your email. Email Address About Arecor TherapeuticsArecor Therapeutics (LON:AREC) (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.View Arecor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?Buy the Dip? Broadcom's AI Moat Is Wider Than EverThe Market Has Ollie’s Bargain Outlet Completely WrongBroadcom's Whiplash: Shares Tank After Pre-Earnings SurgeMacy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains CautiousThe Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
